Cargando…
Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
Small intestinal metastases from primary lung cancer are rare. Such patients have a poor prognosis. Early diagnosis of small intestinal metastases is difficult because of the low incidence of clinically apparent symptoms. The standard treatment for small intestinal metastases has not been establishe...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225853/ https://www.ncbi.nlm.nih.gov/pubmed/30464529 http://dx.doi.org/10.2147/OTT.S178985 |
_version_ | 1783369864097824768 |
---|---|
author | Chen, Hua-fei Zhang, Qu-xia Zhu, You-cai Du, Kai-qi Li, Xiao-feng Wu, Li-xin Wang, Wen-xian Xu, Chun-wei |
author_facet | Chen, Hua-fei Zhang, Qu-xia Zhu, You-cai Du, Kai-qi Li, Xiao-feng Wu, Li-xin Wang, Wen-xian Xu, Chun-wei |
author_sort | Chen, Hua-fei |
collection | PubMed |
description | Small intestinal metastases from primary lung cancer are rare. Such patients have a poor prognosis. Early diagnosis of small intestinal metastases is difficult because of the low incidence of clinically apparent symptoms. The standard treatment for small intestinal metastases has not been established. A 69-year-old Chinese man presented for evaluation of a tumor in the right lower lung and mediastinal lymph node enlargement on clinical examination. The clinical stage was cT(2)N(2)M(0) (stage IIIA). Histologic examination of the tumor revealed lung adenocarcinoma. He could not tolerate surgery; hence, he received two chemotherapy regimens. However, the disease progressed. He had bloating after chemotherapy and decreased flatus. An abdominal CT scan showed an intestinal effusion with local intestinal obstruction. Medical treatment was ineffective; hence, he underwent a diagnostic laparoscopy. The pathologic evaluation suggested an intestinal metastatic adenocarcinoma from the primary lung cancer. Based on an real-time PCR assay, the tumor had a ROS1 fusion and responded well to crizotinib. The progression-free survival was 7 months. Physicians must be aware of the possibility of intestinal metastases from primary lung cancer. With an accurate diagnosis and thorough evaluation, patients may benefit from targeted therapy. |
format | Online Article Text |
id | pubmed-6225853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62258532018-11-21 Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib Chen, Hua-fei Zhang, Qu-xia Zhu, You-cai Du, Kai-qi Li, Xiao-feng Wu, Li-xin Wang, Wen-xian Xu, Chun-wei Onco Targets Ther Case Report Small intestinal metastases from primary lung cancer are rare. Such patients have a poor prognosis. Early diagnosis of small intestinal metastases is difficult because of the low incidence of clinically apparent symptoms. The standard treatment for small intestinal metastases has not been established. A 69-year-old Chinese man presented for evaluation of a tumor in the right lower lung and mediastinal lymph node enlargement on clinical examination. The clinical stage was cT(2)N(2)M(0) (stage IIIA). Histologic examination of the tumor revealed lung adenocarcinoma. He could not tolerate surgery; hence, he received two chemotherapy regimens. However, the disease progressed. He had bloating after chemotherapy and decreased flatus. An abdominal CT scan showed an intestinal effusion with local intestinal obstruction. Medical treatment was ineffective; hence, he underwent a diagnostic laparoscopy. The pathologic evaluation suggested an intestinal metastatic adenocarcinoma from the primary lung cancer. Based on an real-time PCR assay, the tumor had a ROS1 fusion and responded well to crizotinib. The progression-free survival was 7 months. Physicians must be aware of the possibility of intestinal metastases from primary lung cancer. With an accurate diagnosis and thorough evaluation, patients may benefit from targeted therapy. Dove Medical Press 2018-11-05 /pmc/articles/PMC6225853/ /pubmed/30464529 http://dx.doi.org/10.2147/OTT.S178985 Text en © 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Case Report Chen, Hua-fei Zhang, Qu-xia Zhu, You-cai Du, Kai-qi Li, Xiao-feng Wu, Li-xin Wang, Wen-xian Xu, Chun-wei Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib |
title | Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib |
title_full | Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib |
title_fullStr | Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib |
title_full_unstemmed | Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib |
title_short | Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib |
title_sort | intestinal metastasis from primary ros1-positive lung adenocarcinoma cancer patients responding to crizotinib |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225853/ https://www.ncbi.nlm.nih.gov/pubmed/30464529 http://dx.doi.org/10.2147/OTT.S178985 |
work_keys_str_mv | AT chenhuafei intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib AT zhangquxia intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib AT zhuyoucai intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib AT dukaiqi intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib AT lixiaofeng intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib AT wulixin intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib AT wangwenxian intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib AT xuchunwei intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib |